**Drug Pricing Overview** Drug pricing remains a critical issue in the healthcare landscape, affecting affordability and access to essential medications for millions. As rising costs continue to burden patients and healthcare systems, recent developments highlight the complexities of pricing strategies and regulatory efforts. For instance, recent analysis reveals that exempting orphan drugs from Medicare’s new drug-pricing pilots could significantly diminish anticipated savings, stoking biotech lobbying efforts to protect rare-disease therapies from price negotiations. Additionally, the Michigan Supreme Court's decision to allow an investigation into Eli Lilly's insulin pricing underscores the growing scrutiny of pharmaceutical companies' pricing practices. Meanwhile, a report indicates that U.S. drugmakers raised prices on 350 medications despite mounting pressures for reform. These developments suggest a volatile environment where ongoing advocacy and legislative changes could reshape the future of drug pricing, presenting both challenges and opportunities for stakeholders. As policymakers and companies navigate these turbulent waters, the implications for patients, providers, and the pharmaceutical industry are profound, urging a reevaluation of price-setting mechanisms and their impact on public health.